

RECEIVED  
CENTRAL OFFICEApplication No. 09/724,575  
Preliminary Amendment dated January 24, 2005

JAN 24 2005

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-10. (Canceled)

11. (Currently Amended) A method of therapeutically treating a patient suffering from Alzheimer's disease ~~a disorder characterized by amyloid deposition in a mammalian subject~~, comprising administering to the ~~patient~~ subject a dosage of an antibody or antibody fragment thereof that specifically binds synuclein-NAC and a dosage of an antibody or antibody fragment thereof that specifically binds to A $\beta$ , ~~agent effective to produce an immune response comprising antibodies against an amyloid component characteristic of said disorder and an adjuvant that augments the immune response to the amyloid component~~, and thereby therapeutically treat the disease ~~treating the disorder~~.

12-57. (Canceled)

58. (Currently Amended) A method of prophylactically treating a patient susceptible to Alzheimer's disease ~~prophylaxis of a disorder characterized by amyloid deposition in a mammalian subject~~, comprising administering to the ~~patient~~ subject a dosage of an antibody or antibody fragment thereof that specifically binds synuclein-NAC and a dosage of an antibody or antibody fragment thereof that specifically binds to A $\beta$ , ~~agent effective to produce an immune response comprising antibodies against an amyloid component characteristic of said disorder and an adjuvant that augments the immune response to the amyloid component~~, and thereby effecting prophylaxis of the disorder.

59-73. (Canceled)

74. (New) The method of claim 11, wherein the antibodies or antibody fragments are administered with a carrier.

Application No. 09/724,575  
Preliminary Amendment dated January 24, 2005

75. (New) The method of claim 11, wherein the antibodies or antibody fragments are administered intraperitoneally, orally, subcutaneously, intramuscularly, intranasally, topically, or intravenously.

76. (New) The method of claim 11, wherein the antibodies or antibody fragments are administered in multiple dosages over a period of at least six months.

77. (New) The method of claim 11, wherein the antibodies or antibody fragments are administered as a sustained release composition.

78. (New) The method of claim 58, wherein the antibodies or antibody fragments are administered with a carrier.

79. (New) The method of claim 58, wherein the antibodies or antibody fragments are administered intraperitoneally, orally, subcutaneously, intramuscularly, intranasally, topically, or intravenously.

80. (New) The method of claim 58, wherein the antibodies or antibody fragments are administered in multiple dosages over a period of at least six months.

81. (New) The method of claim 58, wherein the antibodies or antibody fragments are administered as a sustained release composition.